JPRN-UMIN000000603
Completed
Phase 2
Multicenter phase II trial of weekly-paclitaxel and oral capecitabine combination therapy for metastatic breast cancer - Phase II study of paclitaxel plus capecitabine (XP) for metastatic breast cancer
Saitama Breast Cancer Clinical Study Group (SBCCSG)0 sites50 target enrollmentFebruary 9, 2007
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Saitama Breast Cancer Clinical Study Group (SBCCSG)
- Enrollment
- 50
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\. severe complication 2\. The brain metastasis which possesses condition 3\. Past history of allergic reaction 4\. Past history of allergic reaction to cremophor EL (polyoxyethylated castor oil) or polysorbate 5\. which has the use history of taxane or 5' DFUR or capecitabine (but the case, after taxane is prescribed in adjuvant or neo ajuvant 6months or more has elapsed, is the register possible not in addition to 1 regimen). 6\. Peripheral neuropathy \>\= grade 2 in prior chemotherapy 7\. Pregnant or lactating women 8\. Doctor's decision for exclusion
Outcomes
Primary Outcomes
Not specified
Similar Trials
Unknown
Phase 2
Phase II Trial of Weekly Intravenous Paclitaxel plus Three Weekly Intraperitoneal Carboplatin Administration for Suboptimally Debulked Ovarian and Primary Peritoneal Carcinoma Incorporating Pharmacogenomic Analysis.Ovarian Cancer, Peritoneal CancerJPRN-UMIN000001713Development Organization for Frontier Medical Therapeutics80
Recruiting
Not Applicable
Phase II trial of weekly Nab-Paclitaxel as second-line chemotherapy for unrecectable or recurrent advanced gastric cancer.Advanced Gastric CancerJPRN-UMIN000015968Tottori University35
Recruiting
Phase 2
Phese 2 trial of weekly nab-paclitaxel in combination with gemcitabine in patients with metastatic breast cancer who have failed prior chemotherapyMetastatic and Recurrenced Breast CancerJPRN-UMIN000009153Toho University Omori Medical Center20
Recruiting
Phase 2
Phese 2 trial of weekly nab-paclitaxel in combination with gemcitabine in partients with metastatic breast cancerJPRN-UMIN000006427Toho University Omori Medical Center40
Completed
Phase 2
Phase II study of weekly paclitaxel (wP) followed by doxorubicin plus paclitaxel (AP) as neo-adjuvant chemotherapy for triple negative Breast Cancer (WePAP)Primary breast cancerJPRN-UMIN000001205Saitama Breast Cancer Clinical Study Group (SBCCSG)63